IKT News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$231.4M

Volume

860.89K

Next Earnings

November 13th

Mkt Cap

$230.2M

Volume

860.89K

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightOver 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.GlobeNewswire Inc. · May 19, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Inhibikase Therapeutics announced the grant of non-qualified stock options to purchase 685,718 shares to five newly-hired non-executive employees under its 2026 Inducement Equity Plan. The options have an exercise price of $1.68 per share with a ten-year term and a standard vesting schedule of 25% after one year followed by 36 monthly installments.GlobeNewswire Inc. · Apr 3, 2026

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded WarrantsInhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.GlobeNewswire Inc. · Nov 21, 2025

BIK-Datenanalyse zeigt: Die Aufnahme von BNPL-Transaktionsdaten in die Kredithistorie könnte fast jedem zweiten „Thin-file-Kunden“ helfen, seine Kreditwürdigkeit zu verbessernA Polish credit bureau analysis reveals that including Buy Now Pay Later (BNPL) transaction data in credit histories could help nearly 40% of 'thin-file' bank customers improve their creditworthiness, with BNPL transactions showing high repayment rates and low default risks.GlobeNewswire Inc. · Jun 27, 2025

Top 10 Small-Cap Stocks to Watch in 2025The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.Investing.com · Dec 20, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s DiseaseCompany expects to report trial results in 4Q24 Company expects to report trial results in 4Q24GlobeNewswire Inc. · Jun 17, 2024

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs- Company positioning multiple assets for late-stage development across its therapeutic pipeline –GlobeNewswire Inc. · Jun 5, 2024

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionBOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,672,452 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered Series A warrants to purchase up to an aggregate of 1,672,452 shares of common stock, and unregistered Class B warrants to purchase up to an aggregate of 1,672,452 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold with one Series A warrant to purchase one share of common stock and one Series B warrant to purchase one share of common stock at a combined purchase price of $1.68. The Series A and Series B warrants will each have an exercise price of $1.68 per share, will be exercisable beginning on the effective date of stockholder approval and, in the case of Series A warrants, will expire on the one-year anniversary from the date of stockholder approval, and in the case of Series B warrants, will expire on the five-year anniversary from the date of stockholder approval.GlobeNewswire Inc. · May 20, 2024

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityCompany to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ETGlobeNewswire Inc. · May 16, 2024

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementBOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it has filed a Request for Withdrawal with the U.S. Securities and Exchange Commission (“SEC”) with respect to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-278844) that it filed with the SEC originally on April 19, 2024. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.GlobeNewswire Inc. · May 15, 2024

IKTInhibikase Therapeutics, Inc. Common Stock

IKT

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any IKT yet.

Related Tickers

Earnings

Mkt Cap

$231.4M

Volume

860.89K

Next Earnings

November 13th